Jordi Casabona

Jordi Casabona

Auto-generated profile, based on publicly available information

Jordi Casabona

Centre Estudis Epidemiològics Sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT), Department de Salut, Generalitat de Catalunya, 08916 Badalona, Spain

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2004 in Eurosurveillance
Verified
Journal Article
Open access
JAJ Almeda
J Almeda
JBJ Casabona Barbarà
J Casabona Barbarà
BSB Simon
B Simon
MGM Gérard
M Gérard
DRD Rey
D Rey
OGon behalf of the Euro-NONOPEP Project group
on behalf of the Euro-NONOPEP Project group
Post-exposure prophylaxis (PEP) is the standard of care for a healthcare worker (HCW) accidentally exposed to an HIV infected source person (occupational exposure), but this is not the case for non-occupational exposures. Very few national guidelines exist for the management of non-occupational exposures to HIV in Europe, contrarily to the occupational ones. The administration of non-occupational post-exposure prophylaxis (NONOPEP) for HIV may be justified by: a biological plausibility, the effectiveness of PEP in animal studies and occupational exposures in humans, efficacy in the prevention of mother to child HIV transmission, and cost effectiveness studies. These evidences, the similar risk of HIV transmission for certain non-occupational exposures to occupational ones, and the conflicting information about attitudes and practices among physicians on NONOPEP led to the proposal of these European recommendations. Participant members of the European project on HIV NONOPEP, funded by the European Commission, and acknowledged as experts in bloodborne pathogen transmission and prevention, met from December 2000 to December 2002 at three formal meetings and a two day workshop for a literature review on risk exposure assessment and the development of the European recommendations for the management of HIV NONOPEP. NONOPEP is recommended in unprotected receptive anal sex and needle or syringe exchange when the source person is known as HIV positive or from a population group with high HIV prevalence. Any combination of drugs available for HIV infected patients can be used as PEP and the simplest and least toxic regimens are to be preferred. PEP should be given within 72 hours from the time of exposure, starting as early as possible and lasting four weeks. All patients should receive medical evaluation including HIV antibody tests, drug toxicity monitoring and counseling periodically for at least 6 months after the exposure. NONOPEP seems to be a both feasible and frequent clinical practice in Europe. Recommendations for its management have been achieved by consensus, but some remain controversial, and they should be updated periodically. NONOPEP should never be considered as a primary prevention strategy and the final decision for prescription must be made on the basis of the patient-physician relationship. Finally, a surveillance system for these cases will be useful to monitor NONOPEP practices in Europe.

3 February 2022 in Current HIV/AIDS Reports
Verified
Journal Article
Closed access
PDF file
DND. K. Nomah
D. K. Nomah
JRJ. Reyes-Urueña
J. Reyes-Urueña
JLJ. M. Llibre
J. M. Llibre
JAJ. Ambrosioni
J. Ambrosioni
FGF. S. Ganem
F. S. Ganem
JCJ. Casabona
J. Casabona

25 November 2021 in Eurosurveillance
Verified
Journal Article
Open access
ASAnnemarie Rinder Stengaard
Annemarie Rinder Stengaard
LCLauren Combs
Lauren Combs
VSVirginie Supervie
Virginie Supervie
SCSara Croxford
Sara Croxford
SDSarika Desai
Sarika Desai
DRDorthe Raben
Dorthe Raben
Background: In Europe, HIV disproportionately affects men who have sex with men (MSM), people who inject drugs (PWID), prisoners, sex workers, and transgender people. Epidemiological data are primarily available from national HIV case surveillance systems that rarely capture information on sex work, gender identity or imprisonment. Surveillance of HIV prevalence in key populations often occurs as independent studies with no established mechanism for collating such information at the European level. Aim: We assessed HIV prevalence in MSM, PWID, prisoners, sex workers, and transgender people in the 30 European Union/European Economic Area countries and the United Kingdom. Methods: We conducted a systematic literature review of peer-reviewed studies published during 2009–19, by searching PubMed, Embase and the Cochrane Library. Data are presented in forest plots by country, as simple prevalence or pooled across multiple studies. Results: Eighty-seven country- and population-specific studies were identified from 23 countries. The highest number of studies, and the largest variation in HIV prevalence, were identified for MSM, ranging from 2.4–29.0% (19 countries) and PWID, from 0.0–59.5% (13 countries). Prevalence ranged from 0.0–15.6% in prisoners (nine countries), 1.1–8.5% in sex workers (five countries) and was 10.9% in transgender people (one country). Individuals belonging to several key population groups had higher prevalence. Conclusion: This review demonstrates that HIV prevalence is highly diverse across population groups and countries. People belonging to multiple key population groups are particularly vulnerable; however, more studies are needed, particularly for sex workers, transgender people and people with multiple risks.

10 December 2021 in Current HIV/AIDS Reports
Verified
Journal Article
Closed access
PDF file
DNDaniel K Nomah
Daniel K Nomah
JRJuliana Reyes-Urueña
Juliana Reyes-Urueña
JLJosep Ma Llibre
Josep Ma Llibre
JAJuan Ambrosioni
Juan Ambrosioni
FGFabiana S Ganem
Fabiana S Ganem
JCJordi Casabona
Jordi Casabona

11 July 2016 in International Journal of STD & AIDS
Verified
Journal Article
Open access
JRJuliana Maria Reyes-Urueña
Juliana Maria Reyes-Urueña
MBMichele Breveglieri
Michele Breveglieri
MFMartina Furegato
Martina Furegato
LFLaura Fernàndez-López
Laura Fernàndez-López
CACristina Agusti
Cristina Agusti
JCJordi Casabona
Jordi Casabona
This study reports the first EU-wide survey of community-based voluntary counselling and testing services (CBVCTs), with the following aims: to assess the current availability of CBVCTs and how the concept of CBVCT is understood; to describe CBVCT modalities and strategies; and to measure the use of rapid tests within CBVCTs. A cross-sectional survey was conducted in two different key informant groups: HIV/AIDS National Focal Points (NFPs) and CBVCTs from the EU and European Free Trade Association (EFTA) countries. A definition of CBVCTs was reached. Descriptive and correspondence analyses were performed. The COBATEST survey was answered by NFPs from 25 of the 32 EU/EFTA countries (response rate of 78.1%), and by 55 CBVCTs in 22 different countries. CBVCTs were functioning in nearly all the responding countries, but only 56% explicitly included them in their national strategic plans. In those that had CBVCTs, the NFPs often lacked reliable information on CBVCTs. In general, CBVCTs in Europe are focused mainly on men who have sex with men, are primarily peer-driven and highly communitarised, whereas CBVCTs targeting other at-risk populations are more medicalised. In addition, the oral test is under-used and in general test performance is highly medicalised. Results show that there is a wide heterogeneity of CBVCTs in Europe, which is varied and highly medicalised. The data provided in this study in conjunction with other deliverables produced by the COBATEST project should contribute to the development of standardised indicators to enable comparisons over time and eventually improve the effectiveness of CBVCTs across Europe.

IBIvet Bayes-Marin
Ivet Bayes-Marin
LELaia Egea-Cortés
Laia Egea-Cortés
JPJorge Palacio-Vieira
Jorge Palacio-Vieira
ABAndreu Bruguera
Andreu Bruguera
JMJocelyn Mesías-Gazmuri
Jocelyn Mesías-Gazmuri
JRJuliana Maria Reyes-Urueña
Juliana Maria Reyes-Urueña
Depressive symptoms are common among people living with HIV (PLWH). The aim of this study was to identify the determinants of depressive symptoms in PLWH in Spain. A total of 1060 PLWH participated in this cross-sectional study and completed the Patient Health Questionnaire-9. The odds ratios for the presence of depressive symptoms were analyzed in a multivariable logistic regression model, including sociodemographic data, comorbidities, health-related behaviors, and social-environment-related variables. We found an overall prevalence of depressive symptoms of 21.42%; by subgroup, namely men, women, and transgender persons, prevalence was 18.13%, 32.81%, and 37.14%, respectively. Moreover, social isolation (OR = 1.05 [CI, 1.02–1.08]) and poor physical and mental quality of life (OR = 1.06 [CI, 1.02–1.09] and OR = 1.13 [CI, 1.09–1.17], respectively) were associated with depressive symptoms. As protective factors, we identified serodisclosure to more people (vs. none; OR = 0.39 [CI, 0.17–0.87]), satisfaction with social roles (OR = 0.86 [CI, 0.79–0.94]), better cognitive function (OR = 0.92 [CI, 0.89–0.95]), and sexualized drug use once in a lifetime (OR = 0.52 [CI, 0.29–0.93]). This study showed a high prevalence of depressive symptoms in PLWH, especially among women and transgender people. The association between psychosocial variables and depressive symptoms highlights the multidimensionality of the problem and identifies areas for intervention. This study found that the management of mental health issues is an area that needs to be improved and tailored to specific groups, with the aim of enhancing the well-being of PLWH.